Abstract
Immunization with effective cancer vaccines can offer a much needed adjuvant therapy to fill the treatment gap after liver resection to prevent relapse of hepatocellular carcinoma (HCC). However, current HCC cancer vaccines are mostly based on native shared-self/tumor antigens that are only able to induce weak immune responses. In this study we investigated whether the HCC-associated self/tumor antigen of alpha-fetoprotein (AFP) could be engineered to create an effective vaccine to break immune tolerance and potently activate CD8 T cells to prevent clinically relevant carcinogen-induced autochthonous HCC in mice. We found that the approach of computer-guided methodical epitope-optimization created a highly immunogenic AFP and that immunization with lentivector expressing the epitope-optimized AFP, but not wild-type AFP, potently activated CD8 T cells. Critically, the activated CD8 T cells not only cross-recognized short synthetic wild-type AFP peptides, but also recognized and killed tumor cells expressing wild-type AFP protein. Immunization with lentivector expressing optimized AFP, but not native AFP, completely protected mice from tumor challenge and reduced the incidence of carcinogen-induced autochthonous HCC. In addition, prime-boost immunization with the optimized AFP significantly increased the frequency of AFP-specific memory CD8 T cells in the liver that were highly effective against emerging HCC tumor cells, further enhancing the tumor prevention of carcinogen-induced autochthonous HCC. Epitope-optimization is required to break immune tolerance and potently activate AFP-specific CD8 T cells, generating effective antitumor effect to prevent clinically relevant carcinogen-induced autochthonous HCC in mice. Our study provides a practical roadmap to develop effective human HCC vaccines that may result in an improved outcome compared to the current HCC vaccines based on wild-type AFP.
Highlights
Liver cancer is the 5th most common cancer and the 3rd most common cause of cancer death in the world [1]
Our study provides a practical roadmap to develop effective human hepatocellular carcinoma (HCC) vaccines that may result in an improved outcome compared to the current HCC vaccines based on wild-type AFP
We found that lv expressing epitope-optimized murine AFP, but not wild-type AFP (wt-AFP), potently activated AFP-specific CD8 T cells, which, critically, cross-recognized wtAFP short peptides, and recognized and killed wt-AFP+ tumor cells
Summary
Liver cancer is the 5th most common cancer and the 3rd most common cause of cancer death in the world [1]. In the United States, the incidence of hepatocellular carcinoma (HCC), the most common type of liver cancer, has almost tripled over the past two decades to an estimated 24,500 new cases in 2013 (American Cancer Society). Treatment options for HCC are limited, which contributes to the dismal 17% 3-year survival rate [1]. Liver resection and transplantation are curative for small tumors, but the lack of post-surgery adjuvant therapies becomes a critical barrier to the success of liver resection, resulting in a 5-year recurrence rate of ~70% [6]. There is an urgent need to develop novel approaches for HCC treatments
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
